Filipiuc Silviu Iulian, Simionescu Natalia, Stanciu Gabriela Dumitrița, Coroaba Adina, Marangoci Narcisa Laura, Filipiuc Leontina Elena, Pinteala Mariana, Uritu Cristina Mariana, Tamba Bogdan Ionel
Centre of Advanced Research in Bionanoconjugates and Biopolymers, "Petru Poni" Institute of Macromolecular Chemistry, 700487 Iasi, Romania.
Advanced Center for Research and Development in Experimental Medicine "Prof. Ostin C. Mungiu", "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
Pharmaceutics. 2025 Feb 27;17(3):307. doi: 10.3390/pharmaceutics17030307.
This work aimed to develop and investigate liposomes incorporating Rhein (Lip-Rh) into the liposomal membrane to enhance the compound's water solubility and oral bioavailability. Liposomes were produced by the thin lipid film technique, with a phosphatidylcholine-to-cholesterol molar ratio of 5:1, dissolved in chloroform and methanol, and thereafter hydrated with ultrapure water and subjected to sonication. The resultant liposomes were studied from a physicochemical perspective using DLS, zeta potential, STEM, UV-Vis, and fluorescence spectroscopies, while oral bioavailability was assessed by fluorescence imaging. Additionally, cell viability assays were performed on tumour cells (MCF-7) in comparison to normal cells (HGFs). The resultant nanoparticles exhibited relatively uniform sizes and narrow size distribution. In vivo fluorescence imaging studies performed on Wistar rats demonstrated significantly enhanced oral bioavailability for Lip-Rh, with rapid absorption into the bloodstream observed one hour after administration, in contrast to the free compound dissolved in vegetable oil. Cell viability assays demonstrated higher cytotoxicity of Lip-Rh towards MCF-7 cells compared to HGF cells, highlighting the selective therapeutic potential of the product. Moreover, we determined that the optimal dose of Rhein per kilogram of body weight, when encapsulated in liposomes, is approximately 2.5 times less than when Rhein is delivered in its unencapsulated form. Lip-Rh is a promising candidate for oncological treatments, presenting three key advantages: increased cytotoxicity towards tumour cells, protection of normal tissues, and the practicality of oral delivery. Additional investigation is required to explore its application in anticancer therapy, whether as monotherapy or as a complementary treatment.
这项工作旨在开发并研究将大黄酸(Lip-Rh)掺入脂质体膜中的脂质体,以提高该化合物的水溶性和口服生物利用度。脂质体通过薄膜分散法制备,磷脂酰胆碱与胆固醇的摩尔比为5:1,溶解于氯仿和甲醇中,然后用超纯水水化并进行超声处理。使用动态光散射(DLS)、ζ电位、扫描透射电子显微镜(STEM)、紫外可见光谱和荧光光谱等方法从物理化学角度对所得脂质体进行了研究,同时通过荧光成像评估口服生物利用度。此外,与正常细胞(人牙龈成纤维细胞,HGFs)相比,对肿瘤细胞(MCF-7)进行了细胞活力测定。所得纳米颗粒呈现出相对均匀的尺寸和较窄的尺寸分布。对Wistar大鼠进行的体内荧光成像研究表明,与溶解在植物油中的游离化合物相比,Lip-Rh的口服生物利用度显著提高,给药后一小时观察到其迅速吸收进入血液。细胞活力测定表明,与HGF细胞相比,Lip-Rh对MCF-7细胞具有更高的细胞毒性,突出了该产品的选择性治疗潜力。此外,我们确定,当大黄酸包裹在脂质体中时,每千克体重的最佳剂量比未包裹形式的大黄酸约少2.5倍。Lip-Rh是肿瘤治疗的一个有前景的候选药物,具有三个关键优势:对肿瘤细胞的细胞毒性增加、对正常组织的保护以及口服给药的实用性。需要进一步研究以探索其在抗癌治疗中的应用,无论是作为单一疗法还是作为辅助治疗。